News Home

Flexion Therapeutics Inc (FLXN) has fallen -1.49% in a Week, Should You Buy?

Friday, October 29, 2021 11:18 AM | InvestorsObserver Analysts
Flexion Therapeutics Inc (FLXN) has fallen -1.49% in a Week, Should You Buy?

Flexion Therapeutics Inc (FLXN) is near the top in its industry group according to InvestorsObserver. FLXN gets an overall rating of 52. That means it scores higher than 52 percent of stocks. Flexion Therapeutics Inc gets a 92 rank in the Drug Manufacturers - Specialty & Generic industry. Drug Manufacturers - Specialty & Generic is number 142 out of 148 industries.

Overall Score - 52
FLXN has an Overall Score of 52. Find out what this means to you and get the rest of the rankings on FLXN!

What do These Ratings Mean?

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. InvestorsObserver makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts. These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

What's Happening With Flexion Therapeutics Inc Stock Today?

Flexion Therapeutics Inc (FLXN) stock is higher by 0.16% while the S&P 500 has fallen -0.14% as of 11:17 AM on Friday, Oct 29. FLXN is higher by $0.02 from the previous closing price of $9.24 on volume of 203,748 shares. Over the past year the S&P 500 has gained 38.67% while FLXN has fallen -22.45%. FLXN lost -$1.92 per share the over the last 12 months. Click Here to get the full Stock Report for Flexion Therapeutics Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App